An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib-Reference-Cited by-同舟云学术

An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib

Published:2017-08-11 Issue:3 Volume:20 Page:322-329
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Diaz-Beveridge R.^ORCID,Bruixola G.,Lorente D.,Caballero J.,Rodrigo E.,Segura Á.,Akhoundova D.,Giménez A.,Aparicio J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s12094-017-1720-4/fulltext.html

Reference30 articles.

1. Globocan. Estimated cancer incidence mapwiLc. 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx . 24th Jan 2014.

2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

4. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) study. Int J Clin Pract. 2010;64:1034–41.

5. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54:2055–63.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological Aspects and Inflammation-Immune Markers in Alcohol and/or Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients Treated With Sorafenib;Gastroenterology Research;2024-02

2. Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma;The Oncologist;2023-04-27

3. Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma;Frontiers in Immunology;2022-12-01

4. Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal;BMC Cancer;2022-07-09

5. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma;Expert Review of Molecular Diagnostics;2022-03-04